^
    Back
    Association details:
    Biomarker:MSI-H/dMMR + RAS mutation
    Cancer:Colorectal Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study.

    Published date:
    01/17/2023
    Excerpt:
    NERDY is a retrospective, monocentric study designed to investigate the effect of ICIm and ICId on dMMR-mCRC basing on RASm….Preliminary clinical results of the NERDY study suggest enhanced activity of ICId compared to ICIm in pts with RASm dMMR-mCRC.
    DOI:
    10.1200/JCO.2023.41.3_suppl.218